

Synagis® (Palivizumab) 2017-2018 Authorization Guidelines

These guidelines follow American Academy of Pediatrics (AAP) recommendations.

Covered Conditions: Max 5 doses (November, December, January, February, March) => 15mg/kg	Data Source 2016 HEDIS Measure Descriptions		Covered by the Alliance	Covered by CCS
	0-12	12-24		
Infants born before 29 weeks gestation with NO CCS Covered Condition	✓		✓	
Infants with chronic lung disease (CLD) of prematurity	✓			✓
Infants with chronic lung disease (CLD) of prematurity and continued requirement for supplemental oxygen, chronic systemic corticosteroid therapy or diuretic therapy		✓		✓
Infants with hemodynamically significant Congenital Heart Disease (CHD) like: Acyanotic heart disease if receiving medication to control CHF <ul style="list-style-type: none"> • Acyanotic heart disease who will require cardiac surgical procedures • Moderate to severe pulmonary hypertension • Cyanotic heart defect if RSV prophylaxis is recommended by a pediatric cardiologist 	✓			✓
Infants who undergo cardiac transplantation during the RSV season	✓	✓		✓
Infants with an anatomic pulmonary anomaly or neuromuscular disorder that impairs the ability to clear secretions from the upper airway due to ineffective cough.	✓			✓
Infants who are profoundly immunocompromised during the RSV season (e.g., solid organ or hematopoietic stem cell transplantation, chemotherapy, severe combined immunodeficiency).	✓	✓		✓
Infants with Cystic Fibrosis and clinical evidence of chronic lung disease (CLD) and/or nutritional compromise.	✓			✓
Infants with Cystic Fibrosis with severe lung disease as evidenced by any of the following: <ul style="list-style-type: none"> * Previous hospitalization for pulmonary exacerbation in the first year of life * Abnormalities on chest radiography/computed tomography that persist when stable) * Weight for length less than the 10th percentile 		✓		✓
<ul style="list-style-type: none"> * Palivizumab is not effective for the treatment of RSV disease. * Prophylaxis in children who are hospitalized for RSV should be discontinued because a second hospitalization in the same season is unlikely to occur. 				

How to Submit an Authorization

Alliance Authorization: Submit Alliance prior authorization forms by fax to (831) 430-5851. A single form is required for the series. Please indicate infant weight on the form. For providers that will administer Synagis in their office, also submit a completed “Statement of Medical Necessity” form.



Provider News

October 18, 2017

Alliance Synagis Ordering and Billing Information: For providers that administer Synagis in their office, the Alliance specialty pharmacy Diplomat must be used. CCAH staff will notify Diplomat when Synagis has been authorized. Diplomat can be reached at (877) 977-9118 (phone) and/or (800) 550-6272 (fax).

CCS Authorization: CCS authorizes Synagis for children who meet CCS Synagis criteria. Please complete a CCS Synagis Request Form and a SAR Request Form. Per CCS NL 13-0914, recommendation and/or documentation of medical necessity must come from the CCS Program authorized pediatric subspecialist, CCS-approved Special Care Center (SCC), or CCS-approved pediatrician authorized in conjunction with a CCS-approved pediatric subspecialist or CCS-approved SCC.

- * Please Note: High Risk Infant Follow-up (HRIF) – only is NOT a CCS condition and thus would not be CCS.

Where to Submit an Authorization

Merced County: Fax your request along with medical documentation and/or chart notes to (209) 724-4001. For more information, please contact CCS of Merced County at (209) 381-1114.

Monterey County: Fax your request along with medical documentation and/or chart notes to (831) 796-8690. For more information, please contact CCS of Monterey County at (831) 755-4747 with any questions.

Santa Cruz County: Fax your request along with medical documentation and/or chart notes to (831) 763-8410. For more information, please contact CCS of Santa Cruz County at (831) 763-8000 with any questions.

Thank you for caring for young, at risk infants. If you have any questions about the Synagis recommendations, please call Michael Blatt, Pharm. D., Alliance Pharmacy Director at (831) 430-2528.